Friday, Aug 07, 2020 | Last Update : 02:13 PM IST

136th Day Of Lockdown

Maharashtra47977931637516792 Tamil Nadu2791442210874571 Andhra Pradesh1967891128701753 Karnataka158254802812897 Delhi1415311271244059 Uttar Pradesh108974634021918 West Bengal86754610231902 Telangana7525753239601 Gujarat65704485612529 Bihar6203140760349 Assam4816233429115 Rajasthan4667932832732 Haryana3779631226448 Odisha3768124483258 Madhya Pradesh3508225414912 Kerala279561629988 Jammu and Kashmir2239614856417 Punjab1901512491462 Jharkhand140705199129 Chhatisgarh10109761369 Uttarakhand8008484795 Goa7075511460 Tripura5520367528 Puducherry4147253758 Manipur301818147 Himachal Pradesh2879171013 Nagaland24056594 Arunachal Pradesh179011053 Chandigarh120671520 Meghalaya9173305 Sikkim7832971 Mizoram5022820
  Life   Health  27 Jul 2020  Bharat Biotech’s Covaxin shows ‘encouraging results’ in phase-I of human trials

Bharat Biotech’s Covaxin shows ‘encouraging results’ in phase-I of human trials

THE ASIAN AGE.
Published : Jul 27, 2020, 3:21 pm IST
Updated : Jul 27, 2020, 3:21 pm IST

Covaxin is one of the only two indigenous COVID vaccine candidates approved for human clinical trials in India

Hyderabad’s Nizams Institute of Medical Sciences (NIMS) has also begun the Phase-1 human clinical trials for Covaxin from July 20.
 Hyderabad’s Nizams Institute of Medical Sciences (NIMS) has also begun the Phase-1 human clinical trials for Covaxin from July 20.

Hyderabad: India’s first indigenously-developed COVID vaccine, Covaxin, is showing ‘encouraging’ results after phase-I of human trials were completed, scientists say.

The trial started around July 17 at the Post-Graduate Institute of Medical Sciences (PGIMS), Rohtak, Haryana and was completed on Saturday. "Part 1 of phase-I of the vaccine trial (is) completed. 50 people across India were administered the vaccine and the results are encouraging. Six people were administered the vaccine on Saturday under part 2 of phase-1," Dr Savita Verma, principal investigator of the vaccine trial team, told ANI.

 

Covaxin is one of the only two vaccines approved for human trials in India, developed by Hyderabad based firm Bharat Biotech in collaboration with Indian Council of Medical Research and the National Institute of Virology. The only other candidate which got the nod from Drugs Controller General of India (DCGI) for human trials is ZyCoV-D, developed by Zydas Cadila Healthcare Ltd.

Hyderabad’s Nizams Institute of Medical Sciences (NIMS) has also begun the Phase-1 human clinical trials for Covaxin from July 20.

NIMS is among the 12 sites selected by the Indian Council for Medical Research for Phase I and II randomised, double-blind and placebo-controlled clinical trials of Covaxin.

 

ICMR Director-General Dr Balram Bhargava had recently asked to fast-track the human clinical trial approvals stating it is one of the "top priority projects which is being monitored at the top-most level of the government" in a letter addressed to these 12 principal investigators.

AIIMS Delhi has also started with the phase-I trial of Covaxin, administered on a 30-year-old on Friday, reports say.

"In the first phase (of the trial), we see the safety of the vaccine, which is of primary importance, and the dose range is calculated. In the second phase, we see how immunogenic it is and that is subsequently followed by phase III, which involves a larger population to assess its efficacy and therapeutic benefit," AIIMS Director Dr Randeep Guleria told PTI.

 

An article by a scientist with the Ministry of Science and Technology published by Press Information Bureau (PIB) states that along with the two Indian vaccines 11 out of 140 vaccine players have entered human trials world over.

Tags: covaxin, bharat biotech, coronavirus vaccine india, zycov-d, zydas cadila healthcare ltd, nizams institute of medical sciences, covaxin vaccine trial, covaxin human trial, covid-19 vaccine status
Location: India, Telangana, Hyderabad